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博士論文題目 Development of Boron-Cluster-containing Redox Nanoparticles for the Use in High 
Performance Boron Neutron Capture Therapy (ハイパフォーマンスな中性子捕捉療法に向けたホウ素ク
ラスタ含有レドックスナノ粒子の開発) 
 
1. Introduction 
  Boron neutron capture therapy (BNCT) is an external beam radiation treatment that is based on the capture reaction 
between thermal neutrons and nonradioactive isotope 10B atoms, producing high linear-energy-transfer (LET) α 
particles and 7Li nuclei with an average total kinetic energy of 2.34 MeV.1-5 These high LET particles are reported to 
traverse 5–9 µm, similar to the diameter of one cell. Thus, cytotoxic effects are believed to occur in 10B atom-containing 
tumor cells only after thermal neutron irradiation, without additional damage to the adjacent healthy tissues. Along the 
development of accelerator, which is smaller and more convenient to be set up in hospital compared with nuclear 
reactor, BNCT will potentially become a generic cancer therapy in the near future.  
  One of the most important issues of BNCT is to develop 10B agents leading satisfactory therapeutic effect without 
strong adverse effect. However, owing to the low molecular weight (LMW), currently clinical applied 10B agents are 
rapidly cleared from the circulatory system after administration. Thus, a high dose is generally required to achieve the 
effective 10B concentration (>20 ppm) in tumors.1 Furthermore, the nonspecific dispersion of LMW 10B agents 
throughout the entire body also tends to increase the risk of both systemic toxicity and adverse effects during the 
thermal neutron irradiation.  
  To improve drug accumulation and retention tendency in the tumor site, nanoscale materials used to deliver 10B 
agents for BNCT have attracted much attention.6-9 Because they are only several tens of nanometers in size and are 
covered by biocompatible polymers such as poly(ethylene glycol) (PEG) as a shell, nanoparticles possessing high 
colloidal stability and non-biofouling characteristics tend to accumulate in tumor tissues as a result of the poorly aligned 
neovascularization and lack of effective lymphatic drainage in these areas, which is referred to as the enhanced 
permeability and retention (EPR) effect.10 So far, most of the reported works that have used this strategy were focused 
on physically encapsulating boron-cluster compounds in liposomes.6,7 However, because the encapsulation of these 
kinds of LMW compounds increases the osmotic pressure of liposome interior, encapsulated boron-cluster compounds 
tend to leak from the liposome into the blood stream, thus leading to a limited therapeutic effect.8  
  It was reported previously that inflammation of tumor microenvironment contributes to resistance to radiotherapy11. 
Nuclea factor-kappa B (NF-κB), which is one of transcription factors, plays a pivotal role in regulation of this kind of 
inflammation-based resistance and blocking of NF-κB to enter nucleus inhibited the adaptive radio resistance of tumor 
cells12. Furthermore, during BNCT, γ-ray emission due to the neutron capture reaction occurring in the tumor tissue also 
causes adverse effects, such as inflammation, by generating a large amount of reactive oxygen species (ROS).13,14 
Therefore, elimination of these original and BNCT-generated ROS is anticipated to increase the radio sensitivity of 
tumor cells and suppress ROS-induced adverse effects. 
  In this work, we synthesized a new anionic block copolymer, PEG-b-poly((closo-dodecaboranyl)thiomethylstyrene) 
(PEG-b-PMBSH), by introducing a negatively charged boron cluster, BSH, to the side chain of the 
poly(chloromethylstyrene) (PCMS) segment in the prepolymer PEG-b-PCMS. Because BSH is a hydrophilic and 
low-toxicity compound, it is much more suitable as a boron source than the hydrophobic carborane used in our previous 
work15. The total molecular weight of this block copolymer is approximately 7,000 Da; thus, it is anticipated to be 
excreted by renal filtration after the disintegration of the polyion complex (PIC) micelle, which was prepared in this 
study.16 Our original nitroxide-radical-containing cationic block copolymer, 
PEG-b-poly(4-(2,2,6,6-tetramethylpiperidine-N-oxyl)aminomethylstyrene) (PEG-b-PMNT) was also synthesized by 
introducing 4-amino-2,2,6,6-tetramethylpiperidine-N-oxyl (4-amino-TEMPO) as the side chain of the PCMS segment 
(Scheme 1), since the nitroxide radical in the TEMPO moiety strongly eliminates ROS. When the anionic 
PEG-b-PMBSH is coupled with the cationic PEG-b-PMNT, boron-cluster-containing redox nanoparticles (BNPs) are 
obtained via PIC formation. Note that because the BSH is conjugated to the block copolymer through a covalent bond, 
it is hard to leak BSH from the nanoparticle. The high charge densities and hydrophobic polystyrene segments are 
expected to increase the colloidal stability under physiological conditions, without complicated chemical cross-linking 
or conjugation reactions. PEG-b-PMNT had been used as an antioxidant polymer drug (redox nanoparticle, RNPN) and 
proved effective for oxidative stress-related diseases such as cerebral and renal ischemia-reperfusion injuries and 
cancer.17-22 We have previously confirmed that RNPN worked well to inhibit NF-κB expression in nucleus of tumor 
tissue and suppressed the inflammation18. Considering of this mechanism, suppression of NF-κB activation might also 
improve therapeutic effect of BNPs because of PEG-b-PMNT as a counterpart of the BNP. Thus, these BNPs are 
anticipated to be a high-performance nanomedicine for BNCT, with the ability to lower the adverse effects by 
scavenging ROS as well as by effectively damaging the tumor cells.  
 
2. Synthesis and Characterization of PEG-b-PMBSH 
  The boron-cluster-conjugated anionic block copolymer PEG-b-PMBSH was synthesized for the first time by 
introducing a clinically applied 10B agent (BSH) to the polystyrene segment of PEG-b-PCMS. Since the nucleophilicity 
of the sulfanyl group of BSH is lower than that of the conventional thiols,23 and rather similar to that of the hydroxyl 
groups, sodium hydride was employed as the metalation agent to convert the thiolate anion, which could then react with 
the chloromethyl group in PCMS, resembling the Williamson ether synthesis method. The increased broad signal 
appearing from 0.5 to 2.0 ppm is assignable to B-H in the boron cluster,23 confirming the immobilization of BSH in the 
polymer.  
 
3. Preparation and Characterization of BNPs 
  The BNPs were prepared by mixing PEG-b-PMBSH and PEG-b-PMNT in phosphate buffer solution with various 
concentrations of boron and various molar ratios of polyanion/polycation. The mixtures under the present preparation 
conditions were transparent, and the main products were micellar structures. The concentration of BNPs affected their 
dispersion stability and caused aggregation under low concentration conditions. An almost completely unimodal 
distribution of nanoparticles (of several tens of nanometer size) was observed by dynamic light scattering (DLS). The 
zeta potential of this complex was close to zero, suggesting complete shielding of the charges of BSH by the PEG outer 
layer.  
    To obtain further information on the colloidal stability of the BNPs, after incubation in mice plasma solution or 
phosphate-buffered saline (PBS) solution containing 10% fetal bovine serum (FBS) for 48 h at 37 °C, size exclusion 
chromatography (SEC) analyses of the BNPs were performed and monitored with a UV detector at 220 nm. A solution 
of BNPs in PBS was used as a control. No decrease of intensity or shift of peak was observed in the presence of mice 
plasma or 10% FBS. Eluates of BNPs in mice plasma solution were collected every 30 s and subjected to ICP-MS and 
DLS analyses. Neither a peak related to the aggregates nor disassembly of the BNPs was observed, confirming their 
highly stable character even in serum proteins. Considering the results above, BNPs have very high colloidal stability 
affording them for the further in vitro and in vivo study. 
 
4. Cytotoxicity and Cellular Uptake of BNPs 
  The cytotoxicity of the BNPs was evaluated by WST-8 cell proliferation assay kit using mouse colorectal carcinoma 
cells (C-26, mouse cell line derived from rectal cancer, BALB/c strain). Generally, cationic polymers and nanoparticles 
with a positive shell are strongly toxic because they readily aggregate with anionic serum proteins and disrupt the 
plasma membrane. For example, the half maximal inhibitory concentration (IC50) values of poly(ethylenimine) at 
different amine concentrations were 3.7 µg/mL (amine: 0.086 mM, MW = 25 kDa) and 12.4 µg/mL (amine: 0.288 mM, 
MW = 1.8 kDa).24 It is interesting to note that BNPs did not show cytotoxicity at all in a relative high concentration of 
10B. It may be because of their neutral surface and high colloidal stability. 
  As mentioned above, the high LET α particles and 7Li nuclei generated from the neutron capture reaction of 10B can 
traverse 5–9 µm, which corresponds with one cell diameter. We strongly believe that the enhancement of cellular 
uptake of the 10B agent by tumor cells and its suppression in normal cells are pivotal for satisfactory BNCT, in order to 
provide more effective damage to the tumor cell while simultaneously suppressing the adverse effects on normal tissues 
caused during the treatment. We evaluated the cellular uptake of BNPs in both the C-26 cell line and human aortic 
endothelial cell line (HAEC) and calculated the uptake ratio. The LMW 10B agents BPA-fructose complex and BSH 
were used as controls. Because BSH is a divalent anion, it is barely able to access the cellular membrane, resulting in 
low cellular uptake. No tumor selectivity for the internalization of BSH was observed. On the other hand, with the 
BPA-fructose complex, the tumor cells showed elevated and selective internalization of BPA, which is ascribed to the 
preferred cellular uptake (especially by tumor cells) of amino acid derivatives of BPA.5 The selective internalization of 
BPA to tumor cells was 2.5-fold higher than to normal cells. The preferential internalization of BNPs to tumor cells 
relative to normal HAECs was 3.3-fold, much higher than that of BPA. This is probably due to the enhanced 
solubilization of the nanoparticles to the membrane lipid bilayer through the PEG fusion process. PEG-modified 
derivatives are widely known to undergo enhanced cellular uptake in many types of cancer cells.25  
  
5. Pharmacokinetics of BNPs in Tumor-bearing Mice 
  The accumulation tendency of boron species in the tumor environment is quite important in practical treatment in 
vivo. Thus, a pharmacokinetics study of the BNPs was performed to investigate their blood circulation tendency and 
tumor accumulation character in C-26 tumor-bearing BALB/c male mice. The 10B concentration in circulating blood 
decreased slowly after intravenous (i.v.) injection (via the tail vein) of BNPs. The long circulation tendency of BNPs is 
important to increase their accumulation in the tumor site, because repeated access to the tumor neovascular wall 
increases leakage in the area via the EPR mechanism. The 10B concentration in tumor tissues reached high level at 48 h 
after administration, and remained at this level until 72 h without significant change. In contrast, the LMW BSH was 
excreted rapidly after 1 h, and almost disappeared in the blood circulation after 24 h without specific tumor 
accumulation.15 Such increased accumulation, prolonged retention in tumor environment, and selective internalization 
to tumor cells of the BNPs might improve the therapeutic effect of thermal neutron treatment, which is described later.  
 
6. Enhanced Boron Neutron Capture Therapeutic Effect by BNPs 
  Thermal neutron irradiation was carried out to evaluate the therapeutic effect of the BNPs in C-26 tumor-bearing 
BALB/c male mice. BPA-fructose complex, RNPN, and PBS administration followed by thermal neutron irradiation, 
and PBS administration without irradiation were used as controls. In both groups of BNPs administration, the 
tumor/blood (T/B) ratio of 10B concentration (one of the most important factors) was higher than that in the 
BPA-fructose complex group. A higher T/B ratio implies lower adverse damage to the circulation system and normal 
tissues during irradiation, because of the lower amount of 10B atoms in the blood vessels. 
  PBS-treated group showed slight tumor suppression effect after thermal neutron irradiation compared to the 
unirradiated group, which is probably because of an effect of γ ray mixed in the neutron ray from the nuclear reactor. It 
is interesting to note that the BNP-treated group, with much lower 10B concentration  in the tumor, suppressed tumor 
growth to the same degree as the BPA-fructose complex group.  
  The therapeutic effect of BNPs on a relatively large tumor model was then investigated. That is, the 10B agents were 
administered to tumors of an average volume of 340 mm3. All 10B samples were administered to tumor-bearing mice by 
i.v. injection via the tail vein 3 d before the thermal neutron irradiation, except for BSH, which was given 1 h before the 
irradiation because of its rapid excretion. In the BNP-treared group, 5 ppm of 10B was observed in the tumor tissues, 
whereas 15 ppm accumulated in the tumor tissues administered BSH. Almost no tumor growth was observed in the 
BNP-treated group, regardless of the low 10B concentration in the tumor tissues. It is again observed that saline-treated 
group showed a slight suppression effect of tumor growth after thermal neutron irradiation, because of γ ray irradiation. 
The relative body weight of the mice in the BNP-treated group kept increasing after a transient period, indicating that 
BNPs did not have significant systemic toxicity.  
 
7. Suppression of Adverse Effects After BNP-assisted BNCT  
  BNCT is considered as a novel cancer therapeutic with low adverse effects, because the thermal neutron ray is a 
benign beam source that does not cause the direct strong ionization damage to healthy cells, which is commonly 
observed in radiotherapy using x ray and γ ray. However, γ rays are still emitted by the neutron capture nuclear reaction 
in tumor cells during the irradiation and cause oxidative damage to healthy tissues by generating ROS,13,14 increasing 
the leukocyte level. Both the BPA-fructose complex and PBS-treated groups presented significantly high leukocyte 
levels after irradiation, compared with the control group and the PBS-treated group without irradiation (PBS-C). On the 
other hand, the BNP and RNPN-treated groups presented almost the same leukocyte level as the controls, indicating that 
the ROS scavenger might work to suppress the increasing in leukocyte level. Let us emphasize again that the BNPs 
worked well to suppress tumor growth despite the very low 10B concentration in tumor tissues, even though it 
eliminated generated ROS, indicating that the observed suppression of tumor progression was not governed by ROS 
generation but rather by the direct attack of the generated active species (such as α ray and 7Li nuclei) by the nuclear 
reaction between the BNPs and thermal neutrons. The generated ROS cause inflammation and adverse effects to the 
entire body. On the basis of these results, it is concluded that the ROS scavenging ability installed in the BNPs helped 
to enhance the therapeutic effect and suppress inflammation, which is one of the main adverse effects of BNCT caused 
by ionization during the irradiation. 
 
8. Discussion 
  With BNPs, a low 10B concentration in tumor tissues led to an ideal tumor suppression effect. On the other hand, 
satisfactory therapeutic effect in the BSH-treated group was not observed. The higher and specific cellular uptake into 
tumor cells of BNPs might contribute effectively to this satisfactory therapeutic effect. In addition, the high tumor 
retention of 10B atoms during the 40 min irradiation in the BNP-treated group might guarantee the required 10B 
concentration in tumor tissue, even with the lower initial boron dose. In the case of LMW 10B agents (BPA and BSH), 
the 10B atoms in tumor tissue kept decreasing as a result of rapid excretion, and thus a higher boron dose might be 
required. From these results, BNPs indeed damaged the tumor cells, and suppressed the tumor growth and metastasis, as 
well as suppressed adverse effects through ROS scavenging activity after thermal neutron irradiation. We strongly 
believe that the BNP is a quality candidate as a boron delivery system for satisfactory BNCT performance. 
 
9. Summary 
ü We have successfully synthesized boron-cluster-containing block copolymer and prepared the 
boron-cluster-containing redox nanoparticles (BNPs) with 36 nm size. 
ü BNPs show high colloidal stability under physiological conditions, low cytotoxicity without irradiation, specific 
cellular uptake into tumor cells compared to normal cells, specific tumor accumulation tendency and longer tumor 
retention time compared with LMW 10B agents. 
ü Satisfactory therapeutic effect by low 10B dose and suppression of adverse effect were confirmed in BNP-assisted 
BNCT. 
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